Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 3
1984 3
1985 4
1986 3
1987 1
1988 2
1990 1
1991 2
1993 2
1994 3
1995 1
1996 1
1997 1
2000 1
2001 1
2003 5
2004 1
2005 1
2006 1
2007 1
2009 5
2010 2
2011 2
2012 2
2013 2
2014 3
2015 4
2016 1
2017 5
2018 4
2019 4
2020 3
2021 3
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE. Collins LG, et al. Am Fam Physician. 2007 Jan 1;75(1):56-63. Am Fam Physician. 2007. PMID: 17225705 Free article. Review.
Smoking remains the predominant risk factor for lung cancer. Lung cancers are categorized as small cell carcinoma or non-small cell carcinoma (e.g., adenocarcinoma, squamous cell carcinoma, large cell carcin …
Smoking remains the predominant risk factor for lung cancer. Lung cancers are categorized as small cell carcinoma or …
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Yatabe Y, et al. J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18. J Thorac Oncol. 2019. PMID: 30572031 Free PMC article.
Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' trea …
Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer d …
Management of centrally located non-small-cell carcinoma.
Backhus LM, Wood DE. Backhus LM, et al. Oncology (Williston Park). 2014 Mar;28(3):215-21. Oncology (Williston Park). 2014. PMID: 24855729 Free article. Review.
Evaluation involves an experienced multidisciplinary team performing careful clinical and invasive-disease staging to identify the best management approach and ascertain the need for multimodality therapy. Preoperative imaging alone is often inaccurate in its ability to de …
Evaluation involves an experienced multidisciplinary team performing careful clinical and invasive-disease staging to identify the best mana …
An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.
Sacco PC, Gridelli C. Sacco PC, et al. Expert Opin Emerg Drugs. 2017 Sep;22(3):213-222. doi: 10.1080/14728214.2017.1369952. Expert Opin Emerg Drugs. 2017. PMID: 28836854 Review.
Various anti-microtubule agents such as taxanes and vinca alkaloids are widely used in the treatment of advanced non-small cell lung cancer (NSCLC) but their use is associated with hematologic toxicity profile, acquired resistance and hypersensitivity reactio …
Various anti-microtubule agents such as taxanes and vinca alkaloids are widely used in the treatment of advanced non-small …
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW, Ahn MJ. Lim SW, et al. Korean J Intern Med. 2019 Jan;34(1):50-59. doi: 10.3904/kjim.2018.179. Epub 2018 Sep 3. Korean J Intern Med. 2019. PMID: 30612418 Free PMC article. Review.
Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). . …
Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chem …
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Bebb DG, et al. Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053. Curr Oncol. 2021. PMID: 33467570 Free PMC article.
These NTRK gene fusions are oncogenic drivers found in most tumour types at a low frequency (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., secretory carcinoma of the salivary gland and of the breast). ...We provide a Canadian …
These NTRK gene fusions are oncogenic drivers found in most tumour types at a low frequency (<5%), and at a higher frequency (>80%) in …
Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.
Clement JM, Sweeney CJ. Clement JM, et al. J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. J Oncol Pract. 2017. PMID: 28045610 Review.
Aggressive metastasis-directed therapy has been used in malignancies such as renal cell carcinoma, non-small-cell lung cancer, and colorectal cancer with some evidence of long-term benefit in selected patients. Recently, it has been propo …
Aggressive metastasis-directed therapy has been used in malignancies such as renal cell carcinoma, non-small …
Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.
Dacic S. Dacic S. J Clin Pathol. 2013 Oct;66(10):870-4. doi: 10.1136/jclinpath-2012-201336. Epub 2013 Jun 25. J Clin Pathol. 2013. PMID: 23801495 Review.
Other types of non-small-cell carcinoma may be considered for such testing if they occur in never-smokers. The landscape of targetable biomarkers in non-small-cell carcinoma is changing rapidly, and demand for clinical testi …
Other types of non-small-cell carcinoma may be considered for such testing if they occur in never-smokers. The l …
80 results